Cannara Q1 Revenue Rises 89%: Key Insights

The TDR Three Key Takeaways:

  1. Revenue Increase: Cannara Biotech’s Q1 2024 net revenues reached $19.5 million, an 89% increase from Q1 2023, indicating a significant rise in sales.
  2. Operational Efficiency: The company’s Q1 2024 operating income was $3.4 million, a 201% increase from the previous year, showing improved efficiency.
  3. Market Share and Product Growth: Cannara expanded its market share in key Canadian provinces and increased its product portfolio to 155 SKUs, also making its first international sale.

Cannara Biotech Inc.(TSXV:LOVE, OTC:LOVFF), a vertically integrated cannabis producer, reported its financial results for the first quarter of 2024. The company, based in Montreal with facilities in Quebec, recorded Q1 net revenues of $19.5 million. This figure represents an 89% increase from the $10.3 million in the same period last year. The report indicates a notable growth in revenue.

The operating income for Cannara in Q1 2024 was $3.4 million, showing a 201% increase from the $1.1 million in Q1 2023. This increase suggests improvements in operational efficiency. The company also reported its eleventh consecutive quarter of positive Adjusted EBITDA, totaling $5.2 million, which may indicate stable financial performance.

Cannara’s net income for this quarter was $2.1 million, compared to $2,951 in Q1 2023. This significant rise in net income suggests an improvement in the company’s profitability.

In Q1 2024, Cannara’s gross cannabis revenue rose by $15.1 million from the same quarter in the previous year, totaling $26.3 million. The gross profit before fair value adjustments was $7.9 million, up 98% from Q1 2023. These numbers could reflect a growing demand for the company’s products and an increase in production efficiency.

Operationally, Cannara expanded its production capacity, activating a 10th growing zone in January 2024. The company sold 1,340,000 units across its brands in Q1 2024, a 99% increase from the same quarter in the previous year. The increase in cannabis flower sales and total units sold could indicate an expanding market presence.

The company’s market share showed growth in several Canadian provinces. It ranked as the fourth-largest licensed producer in Quebec with an 8.7% market share. In Ontario, Cannara held a 3.15% share of the market, and in Alberta, its market share increased by 98.3%. In British Columbia, the market share was 0.84%.

Cannara expanded its product portfolio by 60% to 155 SKUs by the end of Q1 2024. This expansion into new product categories suggests a focus on diversifying its product offerings. Additionally, Cannara completed its first international cannabis product sale to Israel, indicating a step towards expanding its market reach globally.

In terms of capital transactions, Cannara purchased and subsequently cancelled over 286,000 common shares in Q1 2024. The company also granted stock options and RSUs to employees and board members.

At the Annual General Meeting in January 2024, shareholders approved all proposed resolutions. The company’s working capital as of November 30, 2023, was $30.5 million.

Overall, Cannara Biotech Inc.’s first-quarter report for 2024 suggests a period of growth in revenue and market share, alongside an expansion in production capacity and product offerings. The company’s financial results indicate an improvement in profitability and operational efficiency.

Want to keep up to date with all of TDR’s content, subscribe to our daily Baked In newsletter.

You might also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More